BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor APJ.

BioAge completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share. However, less than three months later, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. In response to the news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

Following this news, a federal securities fraud class action complaint was filed which alleges that BioAge and ten of its Officers and Directors made materially false and/or misleading statements in its initial public offering concerning its STRIDES Phase 2 clinical trial and that these investors sustained damages as a result thereof.

Specifically, it is alleged that BioAge’s final prospectus for its IPO represented the significance and benefits of azelaprag for the treatment of obesity in older adults. Defendants touted BioAge’s lead product candidate azelaprag in connection with the Company’s ongoing STRIDES with expectations of topline results in 2025. Defendants also mentioned its collaboration with Lilly’s Chorus clinical development organization who would be advising and assisting on all aspects of the STRIDES trial design and execution. Defendants further discussed the potential for a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in individuals ages 18 years and older. Therefore, the initial public offering represented to the public that there were no safety concerns and the Company expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial. Contrary to these representations, BioAge discontinued the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after several subjects showed elevated levels of liver enzymes warning of potential organ damage. As a result, Defendants discontinued the clinical trial and halted further enrollment. Given the fact that Defendants failure to disclose the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies, Defendants’ statements in BioAge’s registration statement were false and/or materially misleading at the time of the initial public offering.

Current BioAge shareholders who have held BioAge shares since on or shortly after its September 26, 2025 IPO, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to contact us at [email protected] or call 267-507-6085.